Erbitux (cetuximab)

FOLFOXIRI plus Cetuximab or Bevacizumab as 1st-line Treatment of BRAFV600E-mut #coloncancer FIRE-4.5 trial now out in @JCO_ASCO https://t.co/Dme3hX2HeP @StintzingS 👉 if using triplet in mBRAF mCRC, combination with Bev remains the preferable treatment choice @OncoAlert 🚨 (@heinrich_kat)

New @ALLIANCE_org A022004 trial led by .@RonaYaeger @MSKCancerCenter compares treatment w/encorafenib & cetuximab to usual care to reduce chance of cancer recurrence after standard surgery & chemotherapy in pts w/BRAF-mutated stage IIB-III #coloncancer: https://t.co/F1Oxrw98ah (@ALLIANCE_org)

🔥Antitumor Efficacy of Dual Blockade with Encorafenib & Cetuximab with CTx in Human BRAFV600E-mCRC @CCR_AACR https://t.co/PeIO5T2h85 👉interesting preclinical study to evaluate the best combination for targeted and chemotherapies 👇supports BREAKWATER phs-III @myESMO @OncoAlert (@ArndtVogel)

Quali update sulla terapia di mantenimento con #cetuximab del #CRC RAS BRAF wild type? Quali pazienti possono beneficiarne maggiormente? Risponde C.Pinto in un’intervista, a breve sul secondo numero speciale post #ASCO23 di Oncoinfo Ecco un assaggio! 👇🏼 #carcinomacolonretto (@Oncoinfo_it)

Excited to announce that A022004 randomized trial of adjuvant encorafenib + cetuximab vs usual care after standard rx for BRAF V600E stage III, high risk stage II colon cancer is now activated and available to all NCTN sites. @Alliance_org @EileenMOReilly @smitha42 @SyedKazmiMD (@RonaYaeger)

📣 ASCO 2023 Colon Cancer 📣 ➡️ How does the combination of #Encorafenib and #Cetuximab differ from standard adjuvant therapy for patients with #BRAF V600E mutant #ColorectalCancer? @RonaYaeger @sloan_kettering #ASCO23 🔗 https://t.co/k0buXEgFiW (@oncologytube)

Watch this ASCO video of @giconnectInfo expert @StintzingS discussing how liquid biopsy is relevant in verifying mutational status in patients with metastatic #CRC and first-line treatment of #FOLFIRI + #cetuximab for RAS-WT disease https://t.co/Pwl5oYGskn #MedEd #mCRC (@giconnectInfo)

Should we combine it with Cetuximab in GI malignancies ? (@RenoHemonc)

Weekly Cisplatin with RT for me If cannot tolerate platinum, then I prefer Docetaxel over Cetuximab Great trial from @TataMemorial this year in JCO @DrVijayPatil11 @VanitaNoronha #hncsm #radonc https://t.co/B6RYANmQsR (@DrChowdharyMD)

No evidence for con 3weekly cisplat ffor loc. adv. #hnscc H&N SCC. Dear #radonc friends consider concurrent weekly cisplatin or cetuximab for a 73y male with a T3N2c supraglott larynx? @imrtlee @I_Migowski @BhishamCheraMD @KavehZakeriMD @DrHaddadRobert @dr_jm_price @JJCaudell (@RGhalehtaki)

This @SWOG study by @VanMorrisMD is still accruing. It is a Randomized Phase II Trial of Encorafenib and Cetuximab with or Without Nivolumab for Patients with Previously Treated, Microsatellite Stable, BRAF Metastatic and/or Unresectable #ColorectalCancer #crcsm #SWOGonc (@ARosen380)

🔥Encorafenib, Binimetinib & Cetuximab in Previously Untreated BRAF V600E #coloncancer @JCO_ASCO https://t.co/9Ii9etGbte 🔎ANCHOR CRC phs-II 95 pts ✅ORR 47%, mPFS 5.8 mo, mOS 18.3 mo, 60% 2nd line 👉🎯💊feasable in 1st line 👉Binimetenib? CTx? -> BREAKWATER phs-III @myESMO… https://t.co/1vTKv2Bhfk (@ArndtVogel)

1️⃣2️⃣ ✳️KRAS G12C is also now actionable ❗️ ✳️Unlike lung and PDAC, EGFR blockade is a must for the use of KRAS G12C inhibitors! If considering clinical for a CRC patient, look one with an EGFR blockade ! Otherwise off label use of Adagrasib and cetuximab offers good results ‼️ (@IbrahimSahinMD1)

A 2-2. 📌EGFR is an imp GF Receptor in CRC. EGFR MAbs like Cetuximab & Panitumumab are effective for pts with CRC. 📌 But, they are ineffective in RAS mt mCRC as RAS mts are able to continue to transduce signals in the MAPK pathway despite EGFR blockade ! #CRCTrialsChat #CRCSM (@IbrahimSahinMD1)

The BEACON CRC trial introduced a new SOC— encorafenib + cetuximab—for previously treated MSS BRAF V600E mCRC. Investigators have set their sights on further improving outcomes w/ the addition of a third agent, nivolumab @VanMorrisMD @MDAndersonNews #crcsm https://t.co/9tXzCuayQ4 (@OncLive)

Featured today by @MSKLibrary: Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C https://t.co/luQGKTELk1 @RonaYaeger @DrJaredWeiss @MeredithPelster @oncoOuLungCA @LealTiciana @GIcancerDoc @KlempnerSam (@MSKLibrary)

Bowel cancer 🙌breakthrough as scientists find chemotherapy response could be predicted https://t.co/fWp9u703NJ KRAS test can have use beyond its current function of predicting how patients will react to cancer 👉drug cetuximab @DrIanWeissman @SusanChubb1 @SirGeoffPalmer (@Nigelj08223326)

#ASCOGI23 | #mCRC RAS-WT: testata l’efficacia dello switch precoce durante la terapia di prima linea e del re-challenge con #cetuximab in seconda linea. #carcinomacolorettale #tumorecoloretto https://t.co/848OM5mRA1 (@Oncoinfo_it)

My mom's mNSCLC just progressed after 4 years on 1st line osimertinib. A new biopsy showed the original L858R mutation at 6.5%, EGFR copy number 5.3x. What is the best treatment strategy now? Gefitinib cetuximab combination? Thanks. (@love_kb_jun)

Data from the phase 3 BREAKWATER trial showed that encorafenib + cetuximab paired w/ mFOLFOX6 or FOLFIRI had an acceptable safety profile & produced response rates in patients with BRAF V600E–mutated mCRC. @skopetz @MDAndersonNews #crcsm https://t.co/S0T3Jyb9N0 (@OncLive)

ICYMI: Investigators in the phase 2 SWOG S2107 trial are evaluating encorafenib plus cetuximab and nivolumab for patients with previously treated, MSS, unresectable, or mCRC harboring a BRAF V600E mutation. @VanMorrisMD @MDAndersonNews #crcsm https://t.co/DZgTpIh8NM (@OncLive)

🔥Encorafenib, Binimetinib & Cetuximab in 1st line BRAF V600E mutant #colorectalcancer @JCO_ASCO https://t.co/9Ii9etGbte ✅ANCHOR 🗺️phs-2 95 pts 👉ORR 47% 👉mPFS 5.8 mo 👉mOS 18 mo, 67% 2nd line 🤔positive, CTx-free 1st line, but no molecular correlates 🧐BREAKWATER awaited (@ArndtVogel)

Investigators in the phase 2 SWOG S2107 trial are evaluating encorafenib plus cetuximab and nivolumab for patients with previously treated, microsatellite stable, unresectable, or mCRC harboring a BRAF V600E mutation.@VanMorrisMD @MDAndersonNews #crcsm https://t.co/kBiaOV0K3A (@OncLive)

The addition of mFOLFOX6 or FOLFIRI to the combination of encorafenib and cetuximab elicited encouraging antitumor activity and safety in patients with BRAF V600E-mutant metastatic colorectal cancer. @skopetz @MDAndersonNews #crcsm https://t.co/OpDOMn9VMT (@OncLive)

Encorafenib Plus Cetuximab With Nivolumab Under Investigation in BRAF V600E–Mutant mCRC @VanMorrisMD @MDAndersonNews @ASCO #GI23 #crcsm https://t.co/skttft7N69 (@OncLive)

The addition of mFOLFOX6 or FOLFIRI to the combination of encorafenib and cetuximab elicited encouraging antitumor activity and safety in patients with BRAF V600E-mutant metastatic colorectal cancer. @skopetz @MDAndersonNews #crcsm https://t.co/LXo8ENqN1l (@OncLive)

Check out Dr. Benjamin Weinberg @benweinbergmd @LombardiCancer discussing #EGFR Targeted Therapy for #mCRC: Differences Between #Cetuximab and #Panitumumab #CRCSM #ColorectalCancer #OncEd #VuMedi #gicsm #OncTwitter https://t.co/KnHDkMaiK4 (@Sameh_VuMedi)

@hopkinskimmel #HopkinsGI 😃Just learned that Adagrasib + cetux got FDA breakthrough designation based on a 100% PR/SD rate 👉That is a true Hot off the Press Update in GI Cancer👏 @RonaYaeger Adagrasib +/- Cetuximab in CRC with Mutated KRAS G12C https://t.co/L3jIivMCgW (@MPishvaian)

‘Drugging the undruggable’ in KRAS colorectal cancer adagresib vs adagresib and cetuximab - eloquent talk by @GIcancerDoc @MayoClinic. Some patients definitely benefit - more research needed! #mciprecisiononcology @MiamiCancerInst (@BrainTumorDoc)

#TumorBoardTuesday #GI23 The last trial that I was🙏for was dabrafenib, trametinib, irinotecan and cetuximab in BRAF V600E-mut mCRC🖥️by Chen, et al ➡️This4⃣drug combo only resulted in a mPFS of 7.5 mos, and ORR of 30% - which is very similar to encorafenib + cetux alone😔 (@MPishvaian)

Findings from the phase 3 BREAKWATER study indicate that encorafenib plus cetuximab and chemotherapy produces activity and is well-tolerated in metastatic colorectal cancer harboring BRAF V600E mutations. #crcsm #GI23 | @ASCO @skopetz https://t.co/PiW0BEWQm1 (@CancerNetwrk)

Encorafenib Plus Cetuximab and Chemotherapy Demonstrates Safety, Efficacy in BRAF V600E–Mutant mCRC + ctDNA dynamic changes! 🧬 https://t.co/0ndmzAKXg6 via @onclive #GI23 (@DrBonillaOnc)

Delighted to present our Ttd Confidence study in #GI23 about efficacy and safety in rw setting of encorafenib/cetuximab in braf mutant metastatic colorectal cancer @GrupoTTD @flo_encarna @Com_CHUO (@afm1003)

#GI23 ➡️Exciting updates in HER2➕Cancers ✅A Ph 2 trial of trast➕pertuz vs. iri➕cetuximab for HER2➕mCRC: SWOG S1613 👁️KPS Raghav, Abs 140, Pos G18 ✅Zanidatamab➕chemo as 1⃣st-line Tx for HER2➕met GE jxn AdenoCa 👁️Ea Elimova, Abs 347, Pos E8 (@TumorBoardTues)

So for the nth time in 🇲🇺I saw a “senior” clinical oncologist, ask for EGFR mutation analysis for patients with rectal cancer. Few months ago a few of them had attended a CME on role of cetuximab - an antibody inhibits EGFR. 🤷🏻‍♀️ And I am at loss of words! #GlobalOncology (@Geeky_Foodie)

In the phase I/II KRYSTAL-1 trial reported at the NEJM, @RonaYaeger and colleagues found that the KRAS G12C inhibitor adagrasib showed activity alone and in combination with cetuximab in heavily pretreated patients with mCRC and mutated KRAS G12C. (@drlopezgalindo)

Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C | NEJM https://t.co/YeVHzf57cd (@VivekSubbiah)

Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C @NEJM https://t.co/nfvPsDItHU (@weldeiry)

#Adagrasib with or without #Cetuximab in #ColorectalCancer with Mutated #KRAS G12C Adagrasib has antitumor activity 👉https://t.co/XWCmARQCJD @NEJM @RonaYaeger @KlempnerSam #KRASG12C (@davidhenrymd)

Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRASG12C [Dec 21, 2022] @RonaYaeger et al. @NEJM https://t.co/Tsypj77oaT #NCT03785249 #crcsm #PrecisionMedicine (@mtmdphd)

Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C https://t.co/oJQ3H8sGAu (@weldeiry)

Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C- Monotherapy RR=19%,median PFS 5.6 months, in combnation-RR=46%,median PFS 6.9 months. @AnantRamaswamy @HHKhar @ashayoncology @Amolpatel_dr https://t.co/rI0JycZQAe (@DrVijayPatil11)